Dapagliflozin: A Review in Type 2 Diabetes-Reference-Cited by-同舟云学术

Dapagliflozin: A Review in Type 2 Diabetes

Published:2019-06-25 Issue:10 Volume:79 Page:1135-1146
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Dhillon Sohita

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01148-3.pdf

Reference66 articles.

1. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73–9.

2. Wilding J, Fernando K, Milne N, et al. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice. Diabetes Ther. 2018;9(5):1757–73.

3. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33–59.

4. Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(17):2289–312.

5. Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191–209.

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin prevents reproductive damage caused by acute systemic inflammation through antioxidant, anti‐inflammatory, and antiapoptotic mechanisms;Basic & Clinical Pharmacology & Toxicology;2024-09-05

2. The impact of PPAR-γ/Nrf-2/HO-1, NF-κB/IL-6/ Keap-1, and Bcl-2/caspase-3/ATG-5 pathways in mitigation of DOX-induced cardiotoxicity in an animal model: The potential cardioprotective role of oxyresveratrol and/or dapagliflozin;Food and Chemical Toxicology;2024-09

3. Safety and efficacy of dapagliflozin in recurrent ascites: a pilot study;2024-08-17

4. Exploring therapeutic targets and molecular mechanisms for treating diabetes mellitus-associated heart failure with Qishen Yiqi dropping pills: A network pharmacology and bioinformatics approach;Medicine;2024-08-02

5. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy;Cell Reports Medicine;2024-08